Fractional Medical Affairs Leadership
Series A and B biotechsFull ownership of your Medical Affairs function. We build your scientific story, set up governance, map key opinion leaders, and put the right infrastructure in place from day one.
Medical Affairs Strategy, Leadership & Execution
Launch-ready Medical Affairs for emerging biotechs
From fractional leadership to launch partnership and targeted projects, we engage in the way your program needs. Our deepest expertise is in first-in-class, rare disease, gene therapy, and complex specialty medicines, and we welcome programs across other therapeutic areas.
The Founder's Track RecordMeet Ruth Haile-Meskale, PharmD, MBA
14 YearsMedical Affairs leadership across pharma and biotech
- Multiple product launches, including the first FDA-approved gene therapy for a genetic disease
- Medical Affairs teams built from the ground up
Award-Winning2025 Novartis US Business Excellence Award
- 3 product launches readied in under 8 months
Why Zamla
Science doesn't speak for itself.
Strong clinical data alone doesn't change practice. Physicians, payers, regulators, and patients need to understand what your data means for them.
That is the work of Medical Affairs, and for an emerging biotech it is easy to start too late or get wrong. Zamla fills the gap between R&D and commercialization. We turn trial results into a clear scientific story and engage key opinion leaders long before launch.
- Traditional consulting firms
- Strategy without execution.
- Marketing agencies
- Tactics without scientific depth.
- Zamla
- Senior Medical Affairs leadership embedded in your team, owning both strategy and execution.
Who We Partner With
Built for the builders.
We work with emerging biotechs at the stage where Medical Affairs matters most and mistakes cost the most.
Ideal Partner ProfileZamla
- Stage
- Phase IIb through early launch
- Asset Type
- First-in-class, rare disease, gene therapy, and complex specialty, with openness to other therapeutic areas
- Typical Need
- Senior Medical Affairs leadership, launch support, or targeted project execution
- The Goal
- Earn scientific credibility with clinicians and stakeholders, launch fully prepared, and get your therapy to the patients who need it
How We Work
We don't just advise. We embed.
We work as part of your team. We join leadership discussions, set strategy, and drive execution alongside your people. Choose the model that fits your stage.
Strategic Launch Partner
Critical inflection pointsFocused support at critical moments. We turn Phase 2 and 3 data into a compelling scientific platform, run high-impact advisory boards, and prepare the field for clinical adoption.
Targeted Project Execution
Defined deliverablesFast delivery of high-stakes work, including publication strategy, medical communication platforms, advisory boards, compliance frameworks, and HEOR alignment.
No fluff. We take direct responsibility for milestones, timelines, and outcomes.
Explore Our ServicesWhat We Deliver
Six disciplines. One integrated plan.
01
Medical Affairs Strategy
Define the unmet need, the patient journey, and what sets your product apart.
02
Scientific Communications
Build your scientific platform, publication plan, and congress strategy.
03
Evidence Generation
Design Phase IIIb/IV and real-world evidence that matters to patients, providers, and payers.
04
Medical Education
Create education that improves physician knowledge, confidence, and practice.
05
Stakeholder Engagement
Build lasting partnerships with physicians, patient groups, payers, and policymakers.
06
Organizational Planning
Design the team and decision-making structure to grow from a research company into a commercial one.
Meet Our Founder
Ruth Haile-Meskale, PharmD, MBA
Founder & Principal
Behind every breakthrough therapy is a patient who can't afford to wait. Ruth has spent 14 years making sure they don't have to.
Ruth's career spans both the field and the strategy table. As a Medical Science Liaison, she built the trusted relationships with physicians, thought leaders, and patient organizations that remain at the heart of her work. As Senior Medical Director, Rare Renal Diseases, at Novartis, she shaped medical strategy at the highest level. Along the way, she has helped lead multiple product launches. At Spark Therapeutics, she helped launch Luxturna®, the first FDA-approved gene therapy for a genetic disease. At Novartis, she served as medical launch lead for Vanrafia® (atrasentan) in IgA nephropathy. Her team won the 2025 US Business Excellence Award for readying three launches in under eight months, including the first and only treatment for C3 glomerulopathy.
She knows how to build from zero. Ruth was a founding member of the Medical Affairs field teams at ZS Pharma and Spark Therapeutics, creating the training, processes, and KOL strategy those teams were built on. As Head of Medical Affairs Strategy at Chinook Therapeutics, she led a team of medical directors, built a global scientific council, and guided the medical plan through the company's acquisition by Novartis.
Ruth holds a PharmD and an MBA from Mercer University and completed the Rutgers Pharmaceutical Industry Fellowship in Medical Affairs. She serves on the Medical Affairs Professional Society's Medical Strategy & Launch Excellence Working Group. Clients get the rigor of big pharma with the speed and hands-on ownership a growing biotech needs.
- Therapeutic areas
- Rare renal disease · Gene therapy · Nephrology · Hematology · Cardiovascular & thrombosis
- Core expertise
- Launch strategy · Evidence generation · Advisory boards & scientific councils · Publications · Medical education · Field medical team builds
Great science only changes lives when it reaches the bedside, and Medical Affairs is how it gets there. When clinicians truly understand a therapy, they can choose it with confidence, and patients get treatment that changes their lives. I started Zamla so that every promising therapy, no matter the size of the company behind it, reaches the clinicians and patients who need it.
Senior Advisors
Our brain trust.
Our physician and surgeon advisors bring frontline clinical insight and senior executive experience across therapeutic areas, so we ask the right questions and deliver the right answers.
Robert Steven Gerhard, MD
Assistant Professor of Urology, Emory University School of Medicine; Emory University Hospital Midtown and Grady Memorial Hospital
Frontline clinical insight
Ike Ogbaa, MD
Senior Leader, Genentech; Former Chief Medical Officer, Oxia Therapeutics
Launches and Medical Affairs builds
Titte (Srini) Srinivas, MD, MBA, FAST
Chief Medical Officer, Eloxx Pharmaceuticals
Executive and academic leadership
Let's get your therapy to the patients waiting for it.
Tell us where your program stands. In a complimentary 30-minute call, we'll review your Medical Affairs readiness and identify your most important next steps.
Book a Consultation